17 active not recruiting. 17 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Active not recruiting 17 |
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Hepatitis B: new trials by email Literature Review of Hepatitis B trials Research Report on Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102, HT-101 placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 60 | 2025-11-05 | 2026-10-29 |
| A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B BW-20507 with/without NUC, BW-20507 with/without NUC, Peg-IFNa - Chronic Hepatitis B | Phase 2 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 209 | 2025-09-02 | 2026-01-15 |
| A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) AHB-137 - Chronic Hepatitis B | Phase 2 | Active not recruiting | Ausper Biopharma Co., Ltd. | 20 | 2025-07-15 | 2026-08-10 |
| A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) ALG-000184, TDF - Chronic Hepatitis B Infection | Phase 2 | Active not recruiting | Aligos Therapeutics | 200 | 2025-07-15 | 2026-09-11 |
| A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B HTS 20mg, HTS 30mg, HTS 40mg - Chronic Hepatitis B | Phase 2 / Phase 3 | Active not recruiting | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 1444 | 2025-07-01 | 2025-10-02 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B VIR-2218 and peginterferon alfa-2a - Chronic Hepatitis B | Phase 2 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 12 | 2025-01-31 | 2026-10-05 |
| A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102 - Chronic Hepatitis B | Phase 1 / Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 86 | 2024-12-30 | 2026-10-29 |
| Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB) AHB-137, NAs, Placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Ausper Biopharma Co., Ltd. | 105 | 2024-12-13 | 2026-07-29 |
| Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) - Chronic Hepatitis B | Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 116 | 2024-12-04 | 2026-09-11 |
| A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen - Chronic Hepatitis B Virus Infection, Hepatitis B | Phase 2 | Active not recruiting | GlaxoSmithKline | 283 | 2024-11-11 | 2026-07-07 |
| Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) Bepirovirsen, Placebo - Hepatitis B | Phase 2 | Active not recruiting | GlaxoSmithKline | 153 | 2024-09-17 | 2026-07-08 |
| A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis b | Phase 1 / Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 | 2023-12-07 | 2024-11-14 |
| Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 ISA104, Placebo - Chronic Hepatitis b | Phase 1 / Phase 2 | Active not recruiting | Erasmus Medical Center | 24 | 2023-08-04 | 2026-09-15 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B TVAX-008, Placebo - Chronic Hepatitis B Virus | Phase 2 | Active not recruiting | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | 80 | 2023-06-01 | 2025-09-24 |
| Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure) Bepirovirsen, Placebo - Hepatitis B | Phase 2 | Active not recruiting | GlaxoSmithKline | 360 | 2021-12-14 | 2026-06-24 |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection TAF, Placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Gilead Sciences | 150 | 2016-11-01 | 2026-06-18 |
Hepatitis B, Chronic (14) · Acquired Immunodeficiency Syndrome (1) · Diphtheria (1) · Haemophilus Infections (1) · Poliomyelitis (1) · Tetanus (1) · Whooping Cough (1)
Blood-Borne Infections (17) · Communicable Diseases (17) · DNA Virus Infections (17) · Digestive System Diseases (17) · Hepadnaviridae Infections (17) · Hepatitis (17) · Hepatitis, Viral, Human (17) · Infections (17) · Liver Diseases (17) · Virus Diseases (17) · Chronic Disease (14) · Disease Attributes (14) · Hepatitis, Chronic (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14)
Acids (1) · Nucleosides (1) · Poliovirus Vaccine, Inactivated (1) · Saline Solution, Hypertonic (1) · Tenofovir (1) · Vaccines, Combined (1) · entecavir (1) · nas (1) · peginterferon alfa-2a (1)
GlaxoSmithKline (3) · Ausper Biopharma Co., Ltd. (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Suzhou HepaThera Biotech Co., Ltd. (2) · Aligos Therapeutics (1) · Erasmus Medical Center (1) · Gilead Sciences (1) · Grand Theravac Life Sciences (Nanjing) Co., Ltd. (1) · LG Chem (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Shanghai Argo Biopharmaceutical Co., Ltd. (1) · Xi'an Xintong Pharmaceutical Research Co.,Ltd. (1)
China (12) · United States (6) · Taiwan (5) · Canada (4) · France (4) · Hong Kong (4) · Italy (4) · South Korea (4) · Spain (4) · United Kingdom (4) · Brazil (3) · New Zealand (3) · Romania (3) · South Africa (3) · Argentina (2)
Dave Sprengers, MD, PhD (1) · Dazhi Zhang (1) · Jinlin Hou (1) · Marc G Ghany, M.D. (1)
2023 (3), 2016 (1)